Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications

Immunologic Research

Volumn 61, Issue 1-2, 2015, Pages 31-34

  Tsur, Abraham ^a   Hughes, Grant C ^b   Shoenfeld, Yehuda ^a,c   Carp, Howard ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biologics; Immunomodulation; Preterm labor; Progesterone; Recurrent pregnancy loss; T cells

Indexed keywords

BIOLOGICAL PRODUCT; GESTAGEN; PROGESTERONE; BIOLOGICAL FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNITY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RECURRENT PREGNANCY LOSS; ABORTION, HABITUAL; ADULT; BLOOD; FEMALE; INTERDISCIPLINARY COMMUNICATION; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS;

ABORTION, HABITUAL; ADULT; AUTOIMMUNITY; BIOLOGICAL FACTORS; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGESTERONE; PROGESTINS;

EID: 84922332756     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8621-1     Document Type: Article

References (39)

1. Combs CA, Gravett M, Garite TJ, Hickok DE, Lapidus J, Porreco R, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am J Obstet Gynecol. 2014;210(2):125.e1–15. doi:10.1016/j.ajog.2013.11.032.
2. Kim SM, Romero R, Lee J, Mi Lee S, Park CW, Shin Park J, et al. The frequency and clinical significance of intra-amniotic inflammation in women with preterm uterine contractility but without cervical change: Do the diagnostic criteria for preterm labor need to be changed? J Matern Fetal Neonatal Med. 2012;25(8):1212–21. doi:10.3109/14767058.2011.629256.
3. Moura E, Mattar R, de Souza E, Torloni MR, Gonçalves-Primo A, Daher S. Inflammatory cytokine gene polymorphisms and spontaneous preterm birth. J Reprod Immunol. 2009;80(1–2):115–21. doi:10.1016/j.jri.2008.11.007.
4. Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol. 2010;116(2 Pt 1):393–401. doi:10.1097/AOG.0b013e3181e6dbc0.
5. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x.
6. Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy luteectomy evidence. Obstet Gynecol Surv. 1978;33(2):69–81.
7. Peyron R, Aubény E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328(21):1509–13. doi:10.1056/NEJM199305273282101.
8. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, S. DJ, Hoffman BL et al. Placentation, embryogenesis, and fetal development. In: Cunningham FG, Leveno KJ, Bloom SL, Spong CY, S. DJ, Hoffman BL et al., editors. Willimas obstetrics. 24th ed. New York: McGraw-Hill Education/Medical; 2014. p. 106–15.
9. Committee on Practice Bulletins—Obstetrics. TeACoOaG. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120(4):964–73. doi:10.1097/AOG.0b013e3182723b1b.
10. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206(2):124.e1–19. doi:10.1016/j.ajog.2011.12.003.
11. Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med. 1999;341(9):660–6. doi:10.1056/NEJM199908263410906.
12. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000;21(5):514–50. doi:10.1210/edrv.21.5.0407.
13. Okabe H, Makino S, Kato K, Matsuoka K, Seki H, Takeda S. The effect of progesterone on genes involved in preterm labor. J Reprod Immunol. 2014;. doi:10.1016/j.jri.2014.03.008.
14. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013;10:CD003511. doi:10.1002/14651858.CD003511.pub3.
15. Kwak-Kim J, Bao S, Lee SK, Kim JW, Gilman-Sachs A. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. Am J Reprod Immunol. 2014;. doi:10.1111/aji.12234.
16. Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod. 2000;15(Suppl. 1):46–59.
17. Hughes GC. Progesterone and autoimmune disease. Autoimmun Rev. 2012;11(6–7):A502–14. doi:10.1016/j.autrev.2011.12.003.
18. Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat Med. 2013;19(5):548–56. doi:10.1038/nm.3160.
19. Kaushic C, Roth KL, Anipindi V, Xiu F. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J Reprod Immunol. 2011;88(2):204–9. doi:10.1016/j.jri.2010.12.004.
20. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370(23):2211–8. doi:10.1056/NEJMra1213566.
21. Rowe JH, Ertelt JM, Aguilera MN, Farrar MA, Way SS. Foxp3(+) regulatory T cell expansion required for sustaining pregnancy compromises host defense against prenatal bacterial pathogens. Cell Host Microbe. 2011;10(1):54–64. doi:10.1016/j.chom.2011.06.005.
22. Sakiani S, Olsen NJ, Kovacs WJ. Gonadal steroids and humoral immunity. Nat Rev Endocrinol. 2013;9(1):56–62. doi:10.1038/nrendo.2012.206.
23. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50. doi:10.1146/annurev.immunol.25.022106.141702.
24. Prados MB, La Blunda J, Szekeres-Bartho J, Caramelo J, Miranda S. Progesterone induces a switch in oligosaccharyltransferase isoform expression: consequences on IgG N-glycosylation. Immunol Lett. 2011;137(1–2):28–37. doi:10.1016/j.imlet.2011.01.017.
25. Hughes GC, Clark EA. Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity. 2007;40:470–81.
26. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29(2):185–91. doi:10.1007/s00281-007-0072-5.
27. Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci. 2009;286(1–2):114–8. doi:10.1016/j.jns.2009.08.056.
28. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9. doi:10.1056/NEJM199901283400401.
29. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97. doi:10.1016/S0140-6736(08)60453-5.
30. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96. doi:10.1136/ard.2008.105197.
31. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011;38(1):10–20. doi:10.3899/jrheum.100717.
32. Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317(1):32–8. doi:10.1111/nyas.12456.
33. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2006;2:CD000112. doi:10.1002/14651858.CD000112.pub2.
34. Carp HJ, Toder V, Torchinsky A, Portuguese S, Lipitz S, Gazit E, et al. Allogenic leukocyte immunization after five or more miscarriages. Recurrent Miscarriage Immunotherapy Trialists Group. Hum Reprod. 1997;12(2):250–5.
35. Daya S, Gunby J. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent spontaneous abortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol. 1994;32(4):294–302.
36. Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG. 2007;114(2):134–42. doi:10.1111/j.1471-0528.2006.01201.x.
37. Jerzak M, Ohams M, Górski A, Baranowski W. Etanercept immunotherapy in women with a history of recurrent reproductive failure. Ginekol Pol. 2012;83(4):260–4.
38. Scarpellini F, Sbracia M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod. 2009;24(11):2703–8. doi:10.1093/humrep/dep240.
39. Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and maintenance of pregnancy: Is progesterone nature’s immunosuppressant? Ann N Y Acad Sci. 1977;286:384–97.